Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call April 23, 2026 8:00 AM EDT
Company Participants
Thomas Schinecker – Group Chief Executive Officer
Alan Hippe – Chief Financial Officer
Teresa Graham – Chief Executive Officer of Roche Pharmaceuticals
Matthew Sause – Chief Executive Officer
Bruno Eschli – Head of Investor Relations
Conference Call Participants
James Gordon – Barclays Bank PLC, Research Division
Sachin Jain – BofA Securities, Research Division
Peter Verdult – BNP Paribas, Research Division
Sarita Kapila – Morgan Stanley, Research Division
Luisa Hector – Joh. Berenberg, Gossler & Co. KG, Research Division
Graham Glyn Parry – Citigroup Inc., Research Division
James Quigley – Goldman Sachs Group, Inc., Research Division
Simon Baker – Rothschild & Co Redburn, Research Division
Justin Steven Smith – Bernstein Institutional Services LLC, Research Division
Richard Vosser – JPMorgan Chase & Co, Research Division
Matthew Weston – UBS Investment Bank, Research Division
Steve Scala – TD Cowen, Research Division
Michael Leuchten – Jefferies LLC, Research Division
Rajesh Kumar – HSBC Global Investment Research
Presentation
Operator
My name is Henrik, and I’m the technical operator for today’s call. Kindly note that the webinar is being recorded. [Operator Instructions] One last remark, if you would like to follow the presented slides on out as well, please feel free to go to roche.com/investors to download the presentation. At this time, it’s my pleasure to introduce you to Thomas Schinecker, CEO Roche Group.
Thomas Schinecker
Group Chief Executive Officer
Thank you very much, and good morning and good afternoon to everyone. I’m very much excited to share our Q1 2026 results with you. Overall, a very strong performance in sales in the first quarter. And including there are some clinical and regulatory milestones that we have achieved.
Now let’s start on the performance side. Q1 was strong with group sales at plus 6%, driven by pharma with plus 7%. Diagnostics grew plus 3% despite headwinds from the China
